GO
Loading...

Gilead Sciences Inc

More

  • SINGAPORE, July 8- Singapore sovereign investor Temasek Holdings wants to increase its holdings in China's financial services and technology sectors, banking on the long-term growth prospects of the world's second largest economy.

  • LONDON, July 6- The drugs don't work- and neither does the market, when it comes to antibiotics. Totally resistant forms of the lung infection emerged in India just a few years ago and have now been detected worldwide.

  • INSIGHT-How to fix a broken market in antibiotics Sunday, 6 Jul 2014 | 4:59 AM ET

    LONDON, July 6- The drugs don't work- and neither does the market, when it comes to antibiotics. Totally resistant forms of the lung infection emerged in India just a few years ago and have now been detected worldwide.

  • Midday movers: Lorillard, PetSmart, Walgreen & More Thursday, 3 Jul 2014 | 11:58 AM ET

    Some of Thursday's midday movers:

  • Cramer: Six buyable themes in second half Tuesday, 1 Jul 2014 | 6:08 PM ET
    Jim Cramer on Mad Money.

    Cramer says the price action in Tuesday’s market is sending an important message about what to buy in the days ahead.

  • Lightning Round: Yahoo!, Gilead & more Monday, 30 Jun 2014 | 6:51 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Look for more upside in these biotech names: Pro Tuesday, 24 Jun 2014 | 2:48 PM ET

    Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.

  • Early movers: DRI, ORCL, BAC, TWTR, S, SHPG & more Friday, 20 Jun 2014 | 7:36 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • NEW YORK, June 20- In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.

  • Lightning Round: Chiptole, Gilead & more Thursday, 19 Jun 2014 | 6:50 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • LONDON, June 17- European regulators have validated AbbVie's application for an experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus and the therapy is now under accelerated assessment.

  • Shire braces for takeover bids, hires Citi: Sources Monday, 16 Jun 2014 | 2:25 PM ET
    Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc.

    Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.

  • June 13- U.S. regulators have granted priority review for AbbVie Inc's experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus, the company said on Friday. AbbVie said it had submitted in May marketing applications for regulatory approval in the European Union.

  • This company is the best in the world: Robertson Thursday, 12 Jun 2014 | 4:42 PM ET

    This name has a moat around it that is so wide, no one can breach it, legendary investor Julian Robertson told CNBC.

  • NEW YORK, June 11- For U.S. mutual fund investors, this is shaping up to be a year when it pays to go small. In what mutual fund experts call a rarity, tiny funds with less than $100 million in assets under management are either leading or are among the top three or four best performers in every major U.S. stock category tracked by Morningstar for the year through June 10.

  • Investors eye Achillion for next big pharma deal Tuesday, 10 Jun 2014 | 2:20 PM ET
    Achillion web page

    Achillion's been a takeover target for years. But Merck's acquisition of Idenix may mean Achillion's time has come.